Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by elgin1on Dec 22, 2020 3:56pm
254 Views
Post# 32162958

RE:RE:RE:Compass Pathways IS on NASDQ and....

RE:RE:RE:Compass Pathways IS on NASDQ and....

Nokamper ,  MMEd was a mining company a few months ago . You are comparing it to Betr ? Betr is a pharm company that has several products in its pipeline . MMED has one pyshodelic drug that is a combination of LSD and pyclocybin .... level 1 schedule drug . MMED has pulled out over $100 million in pp from financings in a short period of time with a huge promotional pump.  What's their next step ? You should have sold at $6.50 ... feel sorry for anybody holding above $3.50 . 


This reminds me of the classic marijuana frenzy days of bought deals where onto the brokerage houses that took the deal and insiders early were the ones that made any money .

Time will tell. 


I guess Nokamper we can call you Mr.Mindmed .

<< Previous
Bullboard Posts
Next >>